Arca
Skip to content
Tools
Tools

Hyperglycemia

Drug research and approvals for hyperglycemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 139 studies of hyperglycemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 139
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest start dates first, of 139 recruiting on ClinicalTrials.gov ↗

Drug pipeline

7 in phase 3, 4 in phase 2, 6 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Insulin human
Phase 3 Insulin receptor agonist
Insulin pork
Phase 3 Insulin receptor agonist
Insulin lispro
Phase 3 Insulin receptor agonist
Insulin susp isophane recombinant human
Phase 3 Insulin receptor agonist
Liraglutide
Phase 3 Glucagon-like peptide 1 receptor agonist
Insulin glargine
Phase 3 Insulin receptor agonist
Exenatide
Phase 2 Glucagon-like peptide 1 receptor agonist
Pasireotide
Phase 2 Somatostatin receptor 5 agonist
Lanreotide
Phase 2 Somatostatin receptor 5 agonist
Volagidemab
Phase 1 Glucagon receptor inhibitor
LY-2608204
Phase 1 Hexokinase type IV activator
Macupatide
Phase 1
Honey
Early phase 1
Dichloroacetic acid
Early phase 1

How its trials ended

646 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 126 whose ending is known, 50% met their primary endpoint, 11% missed it and 39% stopped early.

  • Completed, result not reported32751%
  • Ongoing11117%
  • Status unknown8213%
  • Met its primary endpoint6310%
  • Stopped: other or unclear264%
  • Stopped: enrollment or feasibility183%
  • Missed its primary endpoint142%
  • Stopped: safety20%
  • Stopped: lack of efficacy10%
  • Stopped: sponsor or business decision10%
  • Stopped: funding10%

Trials authorized in Canada

Newest first; search them all in Canada trials
Feb 28, 2020Adolescent type 1 diabetes treatment with SGLT2I for hyperglycemia & hyperfiltration trialDapagliflozinHospital for Sick ChildrenClosed
Jun 22, 2018Open study to evaluate the efficacy and safety of metformin in individuals with fragile x syndromeMetforminDr Artuela CakuOngoing

FDA orphan designations

Approved first, then open designations, newest first
Feb 17, 2012KorlymFor the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2…Corcept Therapeutics, Inc.Approved
Mar 28, 2018FluasteroneTreatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)Sterotherapeutics, LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.